Atrial Natriuretic Peptide system (ANP system)

The Atrial Natriuretic Peptide (ANP) system is a critical endocrine and paracrine network that maintains cardiovascular and renal homeostasis by regulating blood pressure and fluid volume [Wikipedia, NIH]. It primarily consists of the peptide hormone ANP, its signaling receptor Natriuretic Peptide Receptor A (NPR-A or guanylyl cyclase-A), and the degradation enzyme neprilysin [StatPearls, CV Physiology]. ANP is synthesized and released by cardiac atrial myocytes in response to mechanical stretch caused by volume expansion [NIH, AHA Journals]. Upon binding to NPR-A, it stimulates the production of cyclic guanosine monophosphate (cGMP), which mediates potent vasodilation, increases the glomerular filtration rate, and promotes natriuresis and diuresis [PubMed, NIH]. The system acts as a natural antagonist to the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, providing protective effects against cardiac hypertrophy and fibrosis [StatPearls, AHA Journals]. Therapeutic strategies targeting this system include neprilysin inhibitors like sacubitril, which prevent the breakdown of endogenous peptides, and recombinant analogs such as carperitide and nesiritide used in the management of heart failure [NIH, CV Physiology].

Other names

Natriuretic peptide systemANP pathwayCardiac natriuretic peptide systemANP/BNP system

The ANP system is therapeutically modulated through two primary mechanisms: the inhibition of neprilysin (the enzyme responsible for the degradation of natriuretic peptides) to increase endogenous peptide levels, and the administration of recombinant peptide analogs that act as agonists for the NPR-A receptor. Both approaches lead to increased intracellular cGMP, resulting in systemic vasodilation, enhanced renal sodium and water excretion, and suppression of the renin-angiotensin-aldosterone system.